Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Patients express mixed feelings about AI in healthcare, favoring its use for documentation and administrative tasks while ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision ...

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care ...

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...